Please login to the form below

Not currently logged in
Email:
Password:

Syntaxin

This page shows the latest Syntaxin news and features for those working in and with pharma, biotech and healthcare.

Ipsen strengthens neurology efforts with Syntaxin purchase

Ipsen strengthens neurology efforts with Syntaxin purchase

Ipsen strengthens neurology efforts with Syntaxin purchase. French pharma firm also agrees research deal with Harvard. ... The drug, like Syntaxin's other investigational compounds, is a targeted secretion inhibitor (TSI).

Latest news

  • Oncology bias in pharma deals

    112. Syntaxin/Ipsen. Research and development collaboration. Botulinum toxins. 99. Novozymes Biopharma Sweden/Repligen Corp.

More from news
Approximately 1 fully matching, plus 1 partially matching documents found.

Latest Intelligence

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Videum Health

Videum Health is a premium video platform that offers brands innovative engagement strategies to reach targeted healthcare audiences on a...

Latest intelligence

World Diabetes Day: Interaction and impact of diabetes on mental health
For World Diabetes Day on the 14th November 2018, Nisha Shahrukh - Medical Writer at Mednet Group has written an article depicting the impact diabetes has on mental health. Including...
EU
Innovation in merger control and the impact on the pharmaceutical sector
Is focusing on pipeline products enough to assess regulatory risks?...
Nudge-nudge, think-think
Chris Ross examines the personal complexities of human behaviour – and explains why fun, emotion and peer endorsement could be key to designing effective behavioural change programmes...

Infographics